Clearance of cervical human papillomavirus infections [1]

International Journal of Cancer

Volumn 104, Issue 2, 2003, Pages 255-256

  Vinther, Jeppe ^a   Norrild, Bodil ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BASAL CELL; CELL DIVISION; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNE SYSTEM; INFECTION RATE; LETTER; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVICITIS; UTERINE CERVIX EPITHELIUM; VIRUS INFECTION; WART VIRUS;

ANIMALS; FEMALE; HUMANS; MICE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; T-LYMPHOCYTES; TIME FACTORS; UTERINE CERVICAL DISEASES;

EID: 0037457312     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10922     Document Type: Letter

References (13)

1. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
2. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-1836.
3. Man S, Fiander A. Immunology of human papillomavirus infection in lower genital tract neoplasia. Best Pract Res Clin Obstet Gynaecol 2001;15:701-714.
4. Nakagawa M, Stites DP, Patel S, Farhat S, Scott M, Hills NK, Palefsky JM, Moscicki AB. Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. J Infect Dis 2000;182:595-598.
5. Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R, Abadi M. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 2002; 11:483-488.
6. de Gruijl TD, Bontkes HJ, Stukart MJ, Walboomers JM, Remmink AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ, Scheper RJ. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J Gen Virol 1996;77:2183-2191.
7. de Gruijl TD, Bontkes HJ, Walboomers JM, Stukart MJ, Doekhie FS, Remmink AJ, Helmerhorst TJ, Verheijen RH, Stern PL, Meijer CJ, Scheper RJ. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res 1998;58:1700-1706.
8. Bontkes HJ, de Gruijl TD, van den Muysenberg AJ, Verheijen RH, Stukart MJ, Meijer CJ, Scheper RJ, Stacey SN, Duggan-Keen MF, Stern PL, Man S, Borysiewicz LK, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 2000;88:92-98.
9. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nature Rev Cancer 2002;2:59-65.
10. Wright WE, Shay JW. Historical claims and current interpretations of replicative aging. Nat Biotechnol 2002;20:682-688.
11. Mahmud N, Devine SM, Weller KP, Parmar S, Sturgeon C, Nelson MC, Hewett T, Hoffman R. The relative quiescence of hematopoietic stem cells in nonhuman primates. Blood 2001;97:3061-3068.
12. Rufer N, Brummendorf TH, Kolvraa S, Bischoff C. Christensen K, Wadsworth L, Schulzer M, Lansdorp PM. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med 1999;190:157-167.
13. Kolodka TM, Garlick JA, Taichman LB. Evidence for keratinocyte stem cells in vitro: long term engraftment and persistence of transgene expression from retrovirus-transduced keratinocytes. Proc Natl Acad Sci USA 1998;95:4356-4361.